Rapamycin (sirolimus) is an mTOR inhibitor with immunosuppressive and antiproliferative properties. While traditionally used to prevent organ transplant rejection, it is increasingly studied for its potential role in promoting longevity and reducing age-related decline. Emerging evidence suggests that rapamycin may modulate pathways associated with cellular aging, inflammation, and metabolic function.

This is a compounded preparation. Compounded preparations are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety, efficacy, or quality.